Differentiating Adrenal Adenomas From Nonadenomas Using 18F-FDG PET/CT. Quantitative and Qualitative Evaluation

Academic Radiology

Volumn 14, Issue 4, 2007, Pages 468-475

  Caoili, Elaine M ^a   Korobkin, Melvyn ^a   Brown, Richard K J ^a   Mackie, Gavin ^a   Shulkin, Barry L ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Adrenal; PET; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADRENAL CORTEX ADENOMA; ADRENAL TUMOR; ADULT; AGED; ARTICLE; CALCULATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG UPTAKE; EVALUATION; FEMALE; HUMAN; HUMAN TISSUE; LIVER; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADRENAL GLAND NEOPLASMS; ADRENOCORTICAL ADENOMA; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33947269897     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acra.2007.01.009     Document Type: Article

References (24)

1. Boland G.W., Goldberg M.A., Lee M.J., Mayo-Smith W.W., Dixon J., McNichols M.M., et al. Indeterminate adrenal mass in patients with cancer: Evaluation at PET with 2-(F-18)-fluoro-2-deoxy-D-glucose. Radiology 194 (1995) 131-134
2. Erasmus J.J., Patz Jr. E.F., McAdams H.P., Murray J.G., Herndon J., Coleman R.E., et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 168 (1997) 1357-1360
3. MacManus M.P., Hicks R.J., Matthews J.P., Hogg A., McKenzie A.F., Wirth A., et al. High rate of unsuspected distant metastases by PET in apparent stage III non-small-cell cancer: Implication for radical radiation therapy. Int J Radiat Oncol Biol Phys 50 (2001) 287-293
4. Maurea S., Mainolfi C., Bazzicalupo L., Panico M.R., Imparato C., Alfano B., et al. Imaging of adrenal tumors using FDG PET: Comparison of benign and malignant lesions. AJR Am J Roentgenol 173 (1999) 25-29
5. Yun M., Kim W., Alnafisi N., Lacorte L., Jang S., and Alavi A. F-FDG PET in characterizing adrenal lesions detected on CT and MRI. J Nucl Med 42 (2001) 1795-1799
6. Kumar R., Xiu Y., Yu J.Q., Takalkar A., El-Haddad G., Poteneta S., et al. F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med 45 (2004) 2058-2062
7. 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med 45 (2006) 32-37
8. Boland G.W., Lee M.J., Gazelle G.S., Halpern E.F., McNicholas M.M.J., and Mueller P.R. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol 171 (1998) 201-204
9. Caoili E.M., Korobkin M., Francis I.R., Cohan R.H., and Dunnick N.R. Delayed enhanced CT of lipid-poor adrenal adenomas. AJR Am J Roentgenol 175 (2000) 1411-1415
10. Caoili E.M., Korobkin M., Francis I.R., et al. Adrenal masses: Characterization with combined unenhanced and delayed enhanced CT. Radiology 222 (2002) 629-633
11. Korobkin M., Francis I.R., Kloos R.T., and Dunnick N.R. The incidental adrenal mass. Radiol Clin North Am 34 5 (1996) 1037-1054
12. Korobkin M., Brodeur F.J., Yutzy G.G., et al. Differentiation of adrenal adenomas from nonadenomas using CT attenuation values. AJR Am J Roentgenol 166 (1996) 531-536
13. Lee M.J., Hahn P.F., Papanicolau N., et al. Benign and malignant adrenal masses: CT distinction with attenuation coefficients, size, and observer analysis. Radiology 179 (1991) 415-418
14. Korobkin M., Giordano T.J., Brodeur F.J., et al. Adrenal adenomas: Relationship between histologic lipid and CT and MR findings. Radiology 200 (1996) 743-747
15. Abrams H.L., Spiro R., and Goldstein N. Metastases in carcinoma: Analysis of 1000 autopsied cases. Cancer 3 (1950) 74-85
16. Blake M.A., Slattery J.M.A., Kalra M.K., Halpern E.F., Fischman A.J., Mueller P.R., et al. Adrenal lesions: Characterization with fused PET/CT image in patients with proved or suspected malignancy-initial experience. Radiology 238 (2006) 970-977
17. 18F-FDG PET/CT. J Nucl Med 45 (2004) 1340-1343
18. Boellard R., Krak N.C., Hoekstra O.S., and Lammertsma A.A. Effect of noise, resolution, and ROI definition of the accuracy of standard uptake values: A simulation study. J Nucl Med 45 (2004) 1519-1527
19. Jaskowiak C.J., Bianco J.A., Perlman S.B., and Fine J.P. Influence of reconstruction iterations on 18F-FDG PET/CT standardized uptake values. J Nucl Med 46 (2005) 424-428
20. Wong C.Y., Thie J., Parling-Lynch K.J., Zakalik D., Margolis J.H., Gaskill M., et al. Glucose-normalized standardized uptake value from (18)F-FDG PET in classifying lymphomas. J Nucl Med 46 (2005) 1659-1663
21. Huang S.C. Anatomy of SUV. Nucl Med Biol 27 (2000) 643-646
22. Stahl A., Ott K., Schwaiger M., and Weber W.A. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET. Eur J Nucl Med Mol Imaging 31 (2004) 1471-1479
23. Diederichs C.G., Staib L., Glatting G., Beger H.G., et al. Elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 39 (1998) 1030-1033
24. Zasadny K.R., and Wahl R.L. Standardized uptake values of normal tissues at PET with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose: Variations with body weight and a method for correction. Radiology 189 (1993) 847-850